HIV Cost-effectiveness | Guidance | Program Resources | HIV/AIDS (2022)

What is cost-effectiveness analysis?
Cost-effectiveness analysis (CEA) is a type of economic analysis where both the cost and the outcome (impact, result, effect, benefit, health gain …) of an intervention are evaluated and then expressed in the form of a cost-effectiveness ratio. The numerator of the cost-effectiveness (CE) ratio represents the cost of the intervention associated with one unit of “outcome”. The denominator is the unit of outcome. It can be expressed using many types of measures including: years of life gained, quality-adjusted life years gained (QALYs), new diagnoses, infections averted, and deaths averted. CEA is usually conducted on interventions that are known to be effective.

The CE ratio is a fraction used to compare the relative costs and outcomes of two or more interventions. In Example 1, the outcome measure chosen is “new HIV diagnoses” and the CE ratio of the programs evaluated is expressed in terms of “cost per new HIV diagnosis”. The CE ratio of Program A is $41,667 per new HIV diagnosis. This ratio does not reveal the cost of implementing the program nor the number of new HIV diagnoses detected by the program. However, when comparing the CE ratio of Program A to that of Program B, we can say that Program B is more cost-effective than Program A when CE is measured in terms of “cost per new HIV diagnosis,” because at $7,400 per new HIV diagnosis, Program B is less costly for the same outcome.

Cost per new HIV diagnosis
HIV interventions, such as screening and partner services, are intended to identify HIV-positive persons who are unaware of their infection. When evaluating several such programs in CE analysis, the outcome “new HIV diagnoses” is often used to enable a comparison across these programs; so the CE ratio is expressed in terms of cost per new HIV diagnosis.

Cost per infection averted (IA)
HIV prevention interventions such as syringe exchange programs, counseling for at-risk youth or post-exposure prophylaxis are intended to prevent (avert) infection in HIV-negative persons. Such programs can be evaluated to determine the number of infections prevented that would have otherwise occurred had the intervention not been provided. When evaluating several such programs in CE analysis, the outcome “HIV infections averted” is often used to enable a comparison across these programs; so the CE ratio can be expressed in terms of cost per infection averted.

The lifetime treatment cost of an HIV infection can be used as a conservative threshold value for the cost of averting one infection. Currently, the lifetime treatment cost of an HIV infection is estimated at $379,668 (in 2010 dollars), therefore a prevention intervention is deemed cost-saving if its CE ratio is less than $379,668 per infection averted.

(Video) HRSA’s Ryan White HIV/AIDS Program Recipients Demonstrate Resiliency during COVID-19

As an outcome, the number of HIV infections averted due to a program can be evaluated using different mathematical techniques that vary in complexity and the amount of data or number of assumptions required. Attention should be paid to the timeframe of the intervention effect considered in the evaluation. For example, if the timeframe is one year, then the cost may have to be incurred annually in order to continue to avert the HIV infections.

Cost per life year (LY) gained
HIV treatment interventions, including retention in care and treatment adherence, are in part intended to extend the lives of HIV-positive persons. Such programs can be evaluated to determine the number of additional life years gained (or saved) that otherwise would have been lost to premature death. When evaluating these types of programs in CE analysis, the outcome “life years” often is used to compare them; so the CE ratio can be expressed in terms of cost per life year gained.

Cost per quality-adjusted life year (QALY) gained
As an outcome, life years do not reflect any of the positive or negative effects on the quality of life of the patients receiving an intervention. For example, drug treatment A may provide an additional 2 years of life dominated by hospitalization while drug treatment B may provide an additional 1 year of life without any significant ill effects.

A quality-adjusted life year (QALY) is an outcome measure that considers both the quality and the quantity of life lived. The QALY is based on the number of years of life added by the intervention. Each year in perfect health is assigned the value of 1.0. Each year of less-than-perfect health is assigned a value less than 1.0 down to a value of 0.0 for death. If the extra years would not be lived in full health, for example if the patient would lose a limb, be blind or suffer from worse mental health, then the extra life-years may be given a value of less than 1 to account for this.

HIV interventions intended to improve and/or extend the lives of HIV positive persons can be evaluated to determine the number of additional QALYs gained (or saved) that would have otherwise been lost. When evaluating several such programs in CE analysis, the CE ratio can be expressed in terms of cost per QALY gained.

(Video) Jurisdictional Approach to HIV/Hepatitis C Coinfection in HRSA’s Ryan White HIV/AIDS Program

Most outcome measures, including infections averted, life years gained and new HIV diagnoses, can be translated into QALYs, thereby providing a consistent measure of comparison across many different types of intervention programs.

Cost-effectiveness thresholds

A cost-effectiveness ratio of $50,000 to $100,000 per QALY gained has been long cited in the literature as a conservative threshold for a cost-effective intervention. Traditionally, if an intervention was estimated to cost less than $50,000 to $100,000 per QALY gained, it would be considered cost-effective. However, recent studies have argued that this benchmark is likely too low since the threshold has not been reassessed over time.1 To reflect the advances of modern health care, Braithwaite et al reevaluated the threshold and estimated the plausible range for a cost-effectiveness decision rule to be between $109,000 and $297,000 per QALY saved (in 2003 dollars; $143,000-$388,000 in 2010 dollars).2

What does “cost-saving” mean?

When two or more programs are being compared (intervention vs. comparator), the intervention is labeled as “cost-saving” when both the net outcome of the intervention is greater than or equal to that of the comparator and the cost of the intervention is less than the cost of the comparator. A program can only be deemed cost-saving when it is compared to an alternative. The alternative is typically the status quo or the current standard of care.

(Video) HIV/AIDS Community Information Outreach Program (ACIOP)

In Example 2, Program A is both cheaper and more beneficial than the current standard of care and is therefore a cost-saving alternative. CE ratios cannot be negative.

If the costs of Program A and the Standard of care are borne by the same institution, then the savings will be reaped by that institution. Often, however, the costs of HIV interventions are borne by many distinct entities, including government, health care systems and individuals, and the savings are not realized by any single entity. In addition, the savings may occur over many years.

How to interpret a CE ratio?

At $100,000 per QALY (or at higher thresholds), a program may be considered cost-effective. However, this ratio contains a numerator and a denominator and thus no interpretation can be made as to the annual cost of this program.

In Example 3, both programs A and B have the same measure of cost-effectiveness in terms of cost per QALY gained, however, Program B is more costly to implement than A. Investment in Program B may nonetheless be justified depending on budgetary constraints and the ability to implement for the program in the population and setting considered.

(Video) 25th Anniversary of Ryan White HIV/AIDS Program

If A and B are complementary rather than alternative programs, then they can both be implemented. Implementing Program A and/or B in a particular population and setting requires an evaluation of the number of persons that potentially could be served by the intervention and the resulting overall costs.

(Video) 30 Years of HRSA's Ryan White HIV/AIDS Program

FAQs

What is the most cost effective way of preventing HIV transmission in Africa? ›

The most cost-effective methods of preventing HIV transmission in sub-Saharan Africa include the use of antiretrovirals (ARVs) to prevent mother-to-child transmission (MTCT) as well as the provision of voluntary medical male circumcision (VMMC) to males.

How much money is saved for each new HIV infection that is prevented? ›

Currently, the lifetime treatment cost of an HIV infection is estimated at $379,668 (in 2010 dollars), therefore a prevention intervention is deemed cost-saving if its CE ratio is less than $379,668 per infection averted.

What programs are offered in relation to HIV? ›

In the United States, proven strategies include:
  • HIV testing and linkage to care. ...
  • Antiretroviral therapy. ...
  • Access to condoms and sterile syringes. ...
  • Prevention programs for people living with HIV and their partners. ...
  • Prevention programs for people at high risk of HIV infection. ...
  • Substance abuse treatment.

What amount will be spent on the treatment of HIV AIDS? ›

HIV care involves a type of medication called antiretroviral therapy (ART) and regular visits with your doctor. One study estimated that costs of this care could run anywhere between $1,800 to $4,500 each month during a person's lifetime. Most of this, about 60%, comes from the high cost of ART medications.

How much does PrEP cost South Africa? ›

South Africa approved the use of PrEP in 2015 — it is available in the private health sector at a monthly cost of about R250 and the health department provides it for free at demonstration sites to high risk groups such as sex workers, men who have sex with men and young women.

How effective is PrEP in South Africa? ›

Consistent adherence to PrEP reduces the risk of HIV transmission from sex by > 95%. For those at risk, daily PrEP has been confirmed to be effective in the prevention of sexual and injecting drug use HIV transmission.

Is antiretroviral therapy free? ›

These free antiretroviral (ARV) drugs are available in 160 government and private treatment facilities situated around the country. The DOH also stressed that most of the much-needed HIV drugs are sufficient until the end of the year, with additional buffer stocks.

How much does PrEP cost? ›

A month's supply of Truvada is nearly $2,000 without insurance (a generic version costs $30-$60 per month). Most private health insurance companies, Medicare, and Medicaid will cover the cost. By law, private insurers cannot charge copayments -- the amount you have to pay out of pocket for the drug.

How much does PrEP cost in Africa? ›

In this study, we show that providing injectable contraceptive users with long-acting PrEP is only cost-effective when long-acting drug prices are low or if the HIV incidence remains relatively high. Yearly drug cost of oral PrEP for women in South Africa is estimated to be about $61 per person 22.

How much is a PrEP pill? ›

Cost of HIV Prevention Drug Discouraging People from Doing PrEP Therapy. Truvada costs $2,000 a month. Experts say that out-of-pocket expense is preventing a lot of people from taking the PrEP treatment to prevent HIV infection. A drug doesn't do much good if people don't take it.

Is PrEP effective after 4 days? ›

How long does PrEP take to work? For receptive anal sex (bottoming), PrEP pills reach maximum protection from HIV at about 7 days of daily use. For receptive vaginal sex and injection drug use, PrEP pills reach maximum protection at about 21 days of daily use.

Is PrEP safer than condoms? ›

With the low number of HIV cases among people actively taking PrEP we are now talking about greater than 99 percent effectiveness, in other words, the pill is more effective at preventing HIV than condoms.

When does PrEP become effective? ›

PrEP is not immediately effective

It takes longer to become effective—21 days of daily use—to be effective at preventing HIV after injection of drugs or in people having vaginal sex.

Is antiretroviral therapy free in USA? ›

Patient Assistance Programs (PAPs) are programs administered by pharmaceutical companies to offer free or reduced-cost antiretroviral (ARV) medicines to low-income people living with HIV who are uninsured or underinsured, and who do not qualify for federal assistance programs such as Medicaid, Medicare, or AIDS Drug ...

Can I buy PrEP over the counter in South Africa? ›

Can your GP prescribe PrEP? Yes, because PrEP has been approved by South Africa's Medicines Control Council. You can't go to the chemist and request PrEP over the counter without a doctor's prescription. Your GP would first have to test you for HIV and make sure you're HIV negative.

Is PrEP available in South Africa? ›

As of 2017, PrEP is approved for HIV prevention by an increasing number of countries, including South Africa (the first country in Africa to do so).

Where can I find PrEP in South Africa? ›

PrEP is currently available for MSM and sex workers at no user cost in the public sector at selected state facilities. PrEP is available for MSM at the Ivan Toms Centre for Men's Health in Cape Town (021 447 2844) and Health4Men at Yeoville clinic in Gauteng (011 648 7979 or 072 654 0816).

Can I get PrEP at pharmacy? ›

PrEP is only available by prescription. Any health care provider licensed to write prescriptions can prescribe PrEP; specialization in infectious diseases or HIV medicine is not required.

Videos

1. HIV/AIDS Housing Program Offers Building Blocks for a Better Life
(AlexianBrothersHlth)
2. HRSA's Ryan White HIV/AIDS Program 30th Anniversary
(HRSAtube)
3. The Ryan White HIV/AIDS Program
(HRSAtube)
4. The Ryan White HIV/AIDS Program
(HRSAtube)
5. 25th Anniversary of Ryan White HIV/AIDS Program
(HRSAtube)
6. HRSA's Ryan White HIV/AIDS Program 30th Anniversary
(HRSAtube)

Top Articles

Latest Posts

Article information

Author: Fredrick Kertzmann

Last Updated: 12/13/2022

Views: 5277

Rating: 4.6 / 5 (66 voted)

Reviews: 89% of readers found this page helpful

Author information

Name: Fredrick Kertzmann

Birthday: 2000-04-29

Address: Apt. 203 613 Huels Gateway, Ralphtown, LA 40204

Phone: +2135150832870

Job: Regional Design Producer

Hobby: Nordic skating, Lacemaking, Mountain biking, Rowing, Gardening, Water sports, role-playing games

Introduction: My name is Fredrick Kertzmann, I am a gleaming, encouraging, inexpensive, thankful, tender, quaint, precious person who loves writing and wants to share my knowledge and understanding with you.